KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (2020 - 2025)

Royalty Pharma's Shares Outstanding history spans 6 years, with the latest figure at $148.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 3.71% year-over-year to $148.4 million; the TTM value through Dec 2025 reached $148.4 million, up 3.71%, while the annual FY2025 figure was $148.4 million, 3.71% up from the prior year.
  • Shares Outstanding for Q4 2025 was $50000.0 at Royalty Pharma, down from $429.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $446.0 million in Q4 2024 and bottomed at $50000.0 in Q1 2021.
  • The 5-year median for Shares Outstanding is $145.7 million (2024), against an average of $169.3 million.
  • The largest annual shift saw Shares Outstanding crashed 99.98% in 2022 before it skyrocketed 896474.0% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $433.0 million in 2021, then plummeted by 62.11% to $164.1 million in 2022, then tumbled by 99.97% to $50000.0 in 2023, then skyrocketed by 286156.0% to $143.1 million in 2024, then rose by 3.71% to $148.4 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Shares Outstanding are $148.4 million (Q4 2025), $429.0 million (Q3 2025), and $432.3 million (Q2 2025).